Traduction de «core of health in all » (Français → Néerlandais) :

The core of “health in all policies” is to examine determinants of health that can be altered to improve health, but which are mainly controlled by the policies of sectors other than health.
The core of “health in all policies” is to examine determinants of health that can be altered to improve health, but which are mainly controlled by the policies of sectors other than health. 1.3 Objectives of the performance project Systematic evaluation of health system performance is an on-going

RÉSULTATS CORE – Rapprochement des résultats IFRS des résultats core – Consumer Health (non audités)
CORE RESULTS – Reconciliation from IFRS results to core results – Consumer Health (unaudited)

RÉSULTATS CORE Rapprochement des résultats IFRS des résultats core – Consumer Health – Premier trimestre 2010 (non audité)
CORE RESULTS Reconciliation from IFRS results to core results – Consumer Health – First quarter 2010 (unaudited)

Toutes les divisions ont accompli une excellente performance: la progression du résultat opérationnel core s’est chiffrée à 9% pour Pharmaceuticals, à 24% pour Vaccins et Diagnostic, à 28% pour Sandoz et à 27% pour Consumer Health.
Performance was strong across all divisions: Pharmaceuticals grew core operating income by 9%; Vaccines and Diagnostics by 24%; Sandoz by 28%; and Consumer Health by 27%.

T1 2010 T4 2009 Variation M USD M USD M USD % Pharmaceuticals 2 431 2 215 216 10 Vaccins et Diagnostic 923 653 270 41 Sandoz 450 356 94 26 Consumer Health 288 248 40 16 Produits/charges nets de Corporate –227 –268 41 –15 Résultat opérationnel core 3 865 3 204 661 21
Q1 2010 Q4 2009 Change USD m USD m USD m % Pharmaceuticals 2 431 2 215 216 10 Vaccines and Diagnostics 923 653 270 41 Sandoz 450 356 94 26 Consumer Health 288 248 40 16 Corporate Income & Expense, net –227 –268 41 –15 Core operating income 3 865 3 204 661 21

Pharmaceuticals 2 636 2 431 205 8 Vaccins et Diagnostic 138 923 -785 -85 Sandoz 364 450 -86 -19 Consumer Health 318 288 30 10 Produits/charges nets de Corporate -180 -227 47 -21 Résultat opérationnel « core » 3 276 3 865 -589 -15
Pharmaceuticals 2 636 2 431 205 8 Vaccines and Diagnostics 138 923 -785 -85 Sandoz 364 450 -86 -19 Consumer Health 318 288 30 10 Corporate Income & Expense, net -180 -227 47 -21 Core operating income 3 276 3 865 -589 -15

computer simulation model the Netherlands Ministry of Health Minimal counselling alone Minimal counselling+NRT Intensive counselling+NRT Intensive counselling+Buproprion Telephone counselling Comparator: current practice: 25% of all smokers would follow a smoking cessation program, current practice: 1.3% of smokers uses one of the interventions.
computer simulation model the Netherlands Ministry of Health Minimal counselling alone Minimal counselling+NRT Intensive counselling+NRT Intensive counselling+bupropion Telephone counselling Comparator: current practice: 25% of all smokers would follow a smoking cessation program, current practice: 1.3% of smokers uses one of the interventions.

90 T. VANSWEEVELT, o.c., 145, nr. 155 91 Bolam v Friern Hospital Management Committee (1957) 2 All ER 118-28 92 Loveday v Renton (1991) Med LR, 117 93 Early v Newham Health Authority (1994) 5 Med LR , 214 94 Airedale NHS Trust v Bland (1993) 4 Med LR, 39
91 Bolam v Friern Hospital Management Committee (1957), 2 All ER, 118-128 92 Loveday v Renton (1991) Med. L.R., 117 93 Early v Newham Health Authority (1994) 5 Med. L.R. , 214 94 Airedale NHS Trust v Bland (1993) 4 Med. L.R., 39 95 Re C medical treatment (1998) LloydÊs Rep. Med. 1, 27 ; Penney, Palmer and Canon v East Kent Health

The availability of the whole health information of a patient at any time by all care providers is a central question, linked to the one of the patient electronic medical record, and to the access to it. Two indicators under development reflect this issue: the % of general practices with access to the hospital data of their patient, and the % of
patient electronic medical record, and to the access to it. Two indicators under development reflect this issue: the % of general practices with access to the hospital data of their patient, and the % of

Different possibilities exist for the assessment of health-related quality of life, but not all are useful for pharmaco-economic evaluations.
Different possibilities exist for the assessment of health-related quality of life, but not all are useful for pharmacoeconomic evaluations.